Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free BON Stock Alerts

Bon Natural Life (BON) Competitors

Bon Natural Life logo
$1.28 +0.03 (+2.11%)
Closing price 03:52 PM Eastern
Extended Trading
$1.27 -0.01 (-0.49%)
As of 05:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BON vs. ATRA, ATNM, ALGS, HOWL, and ATHE

Should you be buying Bon Natural Life stock or one of its competitors? The main competitors of Bon Natural Life include Atara Biotherapeutics (ATRA), Actinium Pharmaceuticals (ATNM), Aligos Therapeutics (ALGS), Werewolf Therapeutics (HOWL), and Alterity Therapeutics (ATHE). These companies are all part of the "pharmaceutical products" industry.

How does Bon Natural Life compare to Atara Biotherapeutics?

Bon Natural Life (NASDAQ:BON) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

0.6% of Bon Natural Life shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 26.5% of Bon Natural Life shares are owned by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Atara Biotherapeutics has higher revenue and earnings than Bon Natural Life.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bon Natural Life$18.67M0.56-$2MN/AN/A
Atara Biotherapeutics$120.77M0.34$32.69M$3.121.53

Atara Biotherapeutics has a consensus target price of $6.00, suggesting a potential upside of 26.05%. Given Atara Biotherapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Atara Biotherapeutics is more favorable than Bon Natural Life.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bon Natural Life
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Atara Biotherapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Atara Biotherapeutics has a net margin of 27.07% compared to Bon Natural Life's net margin of 0.00%. Bon Natural Life's return on equity of 0.00% beat Atara Biotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bon Natural LifeN/A N/A N/A
Atara Biotherapeutics 27.07%-79.12%87.55%

Bon Natural Life has a beta of -0.19, meaning that its share price is 119% less volatile than the S&P 500. Comparatively, Atara Biotherapeutics has a beta of -0.3, meaning that its share price is 130% less volatile than the S&P 500.

In the previous week, Atara Biotherapeutics had 20 more articles in the media than Bon Natural Life. MarketBeat recorded 20 mentions for Atara Biotherapeutics and 0 mentions for Bon Natural Life. Atara Biotherapeutics' average media sentiment score of 0.00 beat Bon Natural Life's score of 0.00 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Bon Natural Life Neutral
Atara Biotherapeutics Neutral

Summary

Atara Biotherapeutics beats Bon Natural Life on 10 of the 13 factors compared between the two stocks.

How does Bon Natural Life compare to Actinium Pharmaceuticals?

Bon Natural Life (NASDAQ:BON) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

0.6% of Bon Natural Life shares are owned by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. 26.5% of Bon Natural Life shares are owned by insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Bon Natural Life has higher revenue and earnings than Actinium Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bon Natural Life$18.67M0.56-$2MN/AN/A
Actinium Pharmaceuticals$90K439.25-$48.82M-$1.08N/A

Actinium Pharmaceuticals has a consensus target price of $4.50, suggesting a potential upside of 257.14%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than Bon Natural Life.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bon Natural Life
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Actinium Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Bon Natural Life's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Bon Natural LifeN/A N/A N/A
Actinium Pharmaceuticals N/A -100.85%-47.89%

Bon Natural Life has a beta of -0.19, meaning that its stock price is 119% less volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500.

In the previous week, Bon Natural Life's average media sentiment score of 0.00 equaled Actinium Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Bon Natural Life Neutral
Actinium Pharmaceuticals Neutral

Summary

Actinium Pharmaceuticals beats Bon Natural Life on 6 of the 11 factors compared between the two stocks.

How does Bon Natural Life compare to Aligos Therapeutics?

Bon Natural Life (NASDAQ:BON) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

0.6% of Bon Natural Life shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 26.5% of Bon Natural Life shares are owned by insiders. Comparatively, 4.8% of Aligos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Aligos Therapeutics has a consensus target price of $41.50, suggesting a potential upside of 553.54%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Bon Natural Life.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bon Natural Life
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Aligos Therapeutics
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80

Bon Natural Life has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,106.72%. Bon Natural Life's return on equity of 0.00% beat Aligos Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bon Natural LifeN/A N/A N/A
Aligos Therapeutics -1,106.72%-28.16%-20.01%

In the previous week, Aligos Therapeutics had 1 more articles in the media than Bon Natural Life. MarketBeat recorded 1 mentions for Aligos Therapeutics and 0 mentions for Bon Natural Life. Aligos Therapeutics' average media sentiment score of 0.27 beat Bon Natural Life's score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Bon Natural Life Neutral
Aligos Therapeutics Neutral

Bon Natural Life has a beta of -0.19, meaning that its stock price is 119% less volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500.

Bon Natural Life has higher revenue and earnings than Aligos Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bon Natural Life$18.67M0.56-$2MN/AN/A
Aligos Therapeutics$2.19M17.98-$24.19M-$8.59N/A

Summary

Aligos Therapeutics beats Bon Natural Life on 9 of the 15 factors compared between the two stocks.

How does Bon Natural Life compare to Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by company insiders. Comparatively, 26.5% of Bon Natural Life shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Werewolf Therapeutics presently has a consensus target price of $3.75, suggesting a potential upside of 459.95%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Werewolf Therapeutics is more favorable than Bon Natural Life.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Werewolf Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14
Bon Natural Life
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Bon Natural Life's return on equity of 0.00% beat Werewolf Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Werewolf TherapeuticsN/A -158.82% -69.75%
Bon Natural Life N/A N/A N/A

In the previous week, Werewolf Therapeutics had 9 more articles in the media than Bon Natural Life. MarketBeat recorded 9 mentions for Werewolf Therapeutics and 0 mentions for Bon Natural Life. Bon Natural Life's average media sentiment score of 0.00 beat Werewolf Therapeutics' score of -0.71 indicating that Bon Natural Life is being referred to more favorably in the news media.

Company Overall Sentiment
Werewolf Therapeutics Negative
Bon Natural Life Neutral

Werewolf Therapeutics has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Bon Natural Life has a beta of -0.19, meaning that its share price is 119% less volatile than the S&P 500.

Bon Natural Life has higher revenue and earnings than Werewolf Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Werewolf Therapeutics$1.88M17.31-$60.82M-$1.36N/A
Bon Natural Life$18.67M0.56-$2MN/AN/A

Summary

Werewolf Therapeutics beats Bon Natural Life on 7 of the 13 factors compared between the two stocks.

How does Bon Natural Life compare to Alterity Therapeutics?

Alterity Therapeutics (NASDAQ:ATHE) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

2.1% of Alterity Therapeutics shares are held by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are held by institutional investors. 38.8% of Alterity Therapeutics shares are held by company insiders. Comparatively, 26.5% of Bon Natural Life shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alterity Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Bon Natural Life
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Company Net Margins Return on Equity Return on Assets
Alterity TherapeuticsN/A N/A N/A
Bon Natural Life N/A N/A N/A

In the previous week, Alterity Therapeutics had 2 more articles in the media than Bon Natural Life. MarketBeat recorded 2 mentions for Alterity Therapeutics and 0 mentions for Bon Natural Life. Bon Natural Life's average media sentiment score of 0.00 beat Alterity Therapeutics' score of -0.43 indicating that Bon Natural Life is being referred to more favorably in the news media.

Company Overall Sentiment
Alterity Therapeutics Neutral
Bon Natural Life Neutral

Alterity Therapeutics has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500. Comparatively, Bon Natural Life has a beta of -0.19, meaning that its share price is 119% less volatile than the S&P 500.

Bon Natural Life has higher revenue and earnings than Alterity Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alterity TherapeuticsN/AN/A-$7.87MN/AN/A
Bon Natural Life$18.67M0.56-$2MN/AN/A

Summary

Alterity Therapeutics beats Bon Natural Life on 6 of the 9 factors compared between the two stocks.

Get Bon Natural Life News Delivered to You Automatically

Sign up to receive the latest news and ratings for BON and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BON vs. The Competition

Export
MetricBon Natural LifeCONSM PD IndustryDiscretionary SectorNASDAQ Exchange
Market Cap$10.38M$1.46B$7.12B$11.87B
Dividend YieldN/A3.97%2.87%5.21%
P/E RatioN/A9.9816.9528.47
Price / Sales0.565.043.7460.94
Price / CashN/A16.6913.0036.52
Price / Book0.181.433.566.67
Net Income-$2M$66.99M$267.38M$332.53M
7 Day Performance-2.48%-0.54%-0.86%2.01%
1 Month Performance-0.29%5.15%5.81%9.20%
1 Year PerformanceN/A15.23%10.62%39.59%

Bon Natural Life Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BON
Bon Natural Life
0.3123 of 5 stars		$1.28
+2.1%		N/AN/A$10.38M$18.67MN/A100
ATRA
Atara Biotherapeutics
2.4436 of 5 stars		$5.01
flat		$6.00
+19.8%		N/A$40.98M$120.77M1.61330
ATNM
Actinium Pharmaceuticals
2.1544 of 5 stars		$1.28
flat		$4.50
+251.6%		N/A$40.16M$90KN/A30
ALGS
Aligos Therapeutics
3.6714 of 5 stars		$6.40
flat		$41.50
+548.4%		N/A$39.62M$2.19MN/A90
HOWL
Werewolf Therapeutics
2.6167 of 5 stars		$0.81
flat		$3.75
+361.3%		N/A$39.51M$1.88MN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BON) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel